Published Online: May 17, 2017
Page range: 62 - 65
DOI: https://doi.org/10.1515/arsm-2017-0012
Keywords
© by Angelica Nela Stavar
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.
Hepatitis C virus (HCV) infection affects approximately 180 million people worldwide, which accounts for roughly 2% - 3% of the world’s population. Complications arising from chronic HCV infection include the development of cirrhosis, end stage liver disease, and hepatocellular carcinoma (HCV).
Objective: The study analyses management of anemia with patients in administrating DAA treatment (Telaprevir for 12 weeks).
Material and method: We conducted a study on 24 patients who have concluded the DAA administration period, being now in the period of finalization of standard therapy.
Results: Anemia was the most common adverse reaction,17 patients ( 70.8% ),mild anemia 5 patients (20.8%),medium anemia 8 patients( 47% ), severe anemia 4 patients (24% ). Hemoglobin levels were recorded during therapy, mild Hgb (10.0-10.9g/dl),medium Hgb (9.99-9.9 g/dl),severe Hgb (7.0-8.9 g/dl ), and analyzed the management of anemia in these patients.
In the first 3 months of therapy ( DAA+PegINF and RBV ), doses of DAA not changed.
Any doses of RBV were not modified in patients with mild anemia, in patients with moderate anemia patients received lower doses of RBV, while those with severe anemia patients received lower doses of RBV and red blood cells mass.
Conclusions: Anemia was common adverse reaction in patients with DAA compared with previous results, only PegINF end RBV. Lowering the dose of RBV in the first 3 months, when patients received DAA did not affect SVR.